|Mr. Senthil Vel Sundaram||CEO & Director||581.77k||N/A||1978|
|Dr. Erin Quirk M.D.||Pres & Chief Medical Officer||549.39k||N/A||1971|
|Dr. Weidong Zhong Ph.D.||Co-Founder, Director & Chief Scientific Officer||N/A||N/A||1966|
|Dr. Mark Joseph Vignola||CFO & Treasurer||402.15k||N/A||1978|
|Mr. Seokho Yoon Esq.||COO, Gen. Counsel & Sec.||N/A||N/A||1978|
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.
Terns Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.